299 related articles for article (PubMed ID: 30850240)
1. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
Burny W; Marchant A; Hervé C; Callegaro A; Caubet M; Fissette L; Gheyle L; Legrand C; Ndour C; Tavares Da Silva F; van der Most R; Willems F; Didierlaurent AM; Yarzabal J;
Vaccine; 2019 Mar; 37(14):2004-2015. PubMed ID: 30850240
[TBL] [Abstract][Full Text] [Related]
2. Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
Burny W; Hervé C; Caubet M; Yarzabal JP; Didierlaurent AM
Vaccine; 2022 Apr; 40(19):2714-2722. PubMed ID: 35367070
[TBL] [Abstract][Full Text] [Related]
3. Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.
Burny W; Callegaro A; Bechtold V; Clement F; Delhaye S; Fissette L; Janssens M; Leroux-Roels G; Marchant A; van den Berg RA; Garçon N; van der Most R; Didierlaurent AM;
Front Immunol; 2017; 8():943. PubMed ID: 28855902
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
5. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
Hyer RN; Janssen RS
Vaccine; 2019 Sep; 37(39):5854-5861. PubMed ID: 31431412
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Leroux-Roels G; Marchant A; Levy J; Van Damme P; Schwarz TF; Horsmans Y; Jilg W; Kremsner PG; Haelterman E; Clément F; Gabor JJ; Esen M; Hens A; Carletti I; Fissette L; Tavares Da Silva F; Burny W; Janssens M; Moris P; Didierlaurent AM; Van Der Most R; Garçon N; Van Belle P; Van Mechelen M
Clin Immunol; 2016 Aug; 169():16-27. PubMed ID: 27236001
[TBL] [Abstract][Full Text] [Related]
8. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
Garrett N; Dintwe O; Monaco CL; Jones M; Seaton KE; Church EC; Grunenberg N; Hutter J; deCamp A; Huang Y; Lu H; Mann P; Robinson ST; Heptinstall J; Jensen RL; Pantaleo G; Ding S; Koutsoukos M; Hosseinipour MC; Van Der Meeren O; Gilbert PB; Ferrari G; Andersen-Nissen E; McElrath MJ; Tomaras GD; Gray GE; Corey L; Kublin JG;
J Acquir Immune Defic Syndr; 2024 Aug; 96(4):350-360. PubMed ID: 38916429
[TBL] [Abstract][Full Text] [Related]
10. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
Xie Y; Sun HX; Li D
Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
[TBL] [Abstract][Full Text] [Related]
11. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium.
Weiner J; Lewis DJM; Maertzdorf J; Mollenkopf HJ; Bodinham C; Pizzoferro K; Linley C; Greenwood A; Mantovani A; Bottazzi B; Denoel P; Leroux-Roels G; Kester KE; Jonsdottir I; van den Berg R; Kaufmann SHE; Del Giudice G
Sci Rep; 2019 Dec; 9(1):20362. PubMed ID: 31889148
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.
Moon SH; Shin EC; Noh YW; Lim YT
Vaccine; 2015 Sep; 33(38):4762-9. PubMed ID: 26271830
[TBL] [Abstract][Full Text] [Related]
14. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Janssen JM; Heyward WL; Martin JT; Janssen RS
Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
[TBL] [Abstract][Full Text] [Related]
17. RLJ-NE-299A: a new plant based vaccine adjuvant.
Khajuria A; Gupta A; Singh S; Malik F; Singh J; Suri KA; Satti NK; Qazi GN; Srinivas VK; Gopinathan ; Ella K
Vaccine; 2007 Mar; 25(14):2706-15. PubMed ID: 16872726
[TBL] [Abstract][Full Text] [Related]
18. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses.
Savoji MA; Sereshgi MMA; Ghahari SMM; Asgarhalvaei F; Mahdavi M
Int Immunopharmacol; 2021 Jul; 96():107599. PubMed ID: 33848910
[TBL] [Abstract][Full Text] [Related]
19. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity.
Lugade AA; Bharali DJ; Pradhan V; Elkin G; Mousa SA; Thanavala Y
Nanomedicine; 2013 Oct; 9(7):923-34. PubMed ID: 23542018
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
